Nancy

OBI licensed “OBI-858 Novel Botulinum Toxin Preparation” Intellectual Property Right of Global Aesthetic Medicine to OBIGEN Pharma, Inc.

1. Date of occurrence of the event: Feb 23, 2021 2. Counterparty to the contract or commitment: OBIGEN Pharma, Inc. 3. Relationship with the Company: None 4. Starting and ending …

OBI filed the application of Phase III human clinical study for the active cancer immunotherapy OBI-822, Adagloxad Simolenin, to the drug administrations in Argentina, Brazil, and South Africa

1. Date of occurrence of the event: Feb 17, 2021 2. Company name: OBI Pharma Inc. 3. Relationship to the Company (please enter “head office” or “subsidiaries”): Head Office 4. …

Mr. Michael Chang and five other executives received an acquittal for insider trading case at second instance by Taiwan High Court

Parties to the legal matter: Michael Chang (Chairman); Youe-Kong Shue (Former Vice Chairman); Amy Hung (Former General Manager); Tony Yu (Former Chief Science Officer); Jon-Jin Liao (Former Medical Business Director) …

OBI Pharma Inc. to attend the 39th Annual J.P. Morgan Healthcare Conference

1. Date of the event: Jan 12, 2021 2. Time: 00:00:00 NST 3. Location: Virtual Event 4. Summary: OBI Pharma Inc. to attend the 39th Annual J.P. Morgan Healthcare Conference …

OBI Pharma, Inc. to Present at the 39th J.P. Morgan Healthcare Conference

Taipei, Taiwan. January 6, 2021 — OBI Pharma, Inc., a Taiwan biopharma company (TPEx: 4174), announced that Tillman Pearce, MD., Chief Medical Officer, will present a company and clinical development …

OBI capital increases by issuance of stocks to transfer stocks with Amaran Biotechnology Inc. (Announcement of base day and trading counterparty)

1. Type of merger and acquisition (e.g., merger, spin-off, acquisition, or share transfer): Share transfer 2. Date of occurrence of the event: Dec 31, 2020 3. Names of companies participating …

The active cancer immunotherapy OBI-822, Adagloxad Simolenin, has been granted by National Medical Products Administration (NMPA) to proceed Phase III human clinical study

1. Date of occurrence of the event: Dec 25, 2020 2. Company name: OBI Pharma Inc. 3. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office 4. …